94 related articles for article (PubMed ID: 18036794)
1. Myotoxicity studies of O/W-in situ forming microparticle systems.
Rungseevijitprapa W; Brazeau GA; Simkins JW; Bodmeier R
Eur J Pharm Biopharm; 2008 May; 69(1):126-33. PubMed ID: 18036794
[TBL] [Abstract][Full Text] [Related]
2. Myotoxicity studies of injectable biodegradable in-situ forming drug delivery systems.
Kranz H; Brazeau GA; Napaporn J; Martin RL; Millard W; Bodmeier R
Int J Pharm; 2001 Jan; 212(1):11-8. PubMed ID: 11165816
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of PLGA microsphere size effect on myotoxicity using the isolated rodent skeletal muscle model.
Brazeau GA; Sciame M; al-Suwayeh SA; Fattal E
Pharm Dev Technol; 1996 Oct; 1(3):279-83. PubMed ID: 9552310
[TBL] [Abstract][Full Text] [Related]
4. Assessment of the myotoxicity of pharmaceutical buffers using an in vitro muscle model: effect of pH, capacity, tonicity, and buffer type.
Napaporn J; Thomas M; Svetic KA; Shahrokh Z; Brazeau GA
Pharm Dev Technol; 2000; 5(1):123-30. PubMed ID: 10669926
[TBL] [Abstract][Full Text] [Related]
5. Structure formation and characterization of injectable drug loaded biodegradable devices: in situ implants versus in situ microparticles.
Kranz H; Bodmeier R
Eur J Pharm Sci; 2008 Jul; 34(2-3):164-72. PubMed ID: 18501569
[TBL] [Abstract][Full Text] [Related]
6. Injectability of biodegradable in situ forming microparticle systems (ISM).
Rungseevijitprapa W; Bodmeier R
Eur J Pharm Sci; 2009 Mar; 36(4-5):524-31. PubMed ID: 19124076
[TBL] [Abstract][Full Text] [Related]
7. Biodegradable injectable in situ implants and microparticles for sustained release of montelukast: in vitro release, pharmacokinetics, and stability.
Ahmed TA; Ibrahim HM; Samy AM; Kaseem A; Nutan MT; Hussain MD
AAPS PharmSciTech; 2014 Jun; 15(3):772-80. PubMed ID: 24648158
[TBL] [Abstract][Full Text] [Related]
8. In vitro-in vivo myotoxicity of intramuscular liposomal formulations.
al-Suwayeh SA; Tebbett IR; Wielbo D; Brazeau GA
Pharm Res; 1996 Sep; 13(9):1384-8. PubMed ID: 8893279
[TBL] [Abstract][Full Text] [Related]
9. Effect of particle size of parenteral suspensions on in vitro muscle damage.
Brazeau G; Sauberan SL; Gatlin L; Wisniecki P; Shah J
Pharm Dev Technol; 2011; 16(6):591-8. PubMed ID: 21214423
[TBL] [Abstract][Full Text] [Related]
10. In situ forming microparticle system for controlled delivery of leuprolide acetate: influence of the formulation and processing parameters.
Luan X; Bodmeier R
Eur J Pharm Sci; 2006 Feb; 27(2-3):143-9. PubMed ID: 16243496
[TBL] [Abstract][Full Text] [Related]
11. Method for screening of solid dispersion formulations of low-solubility compounds--miniaturization and automation of solvent casting and dissolution testing.
Shanbhag A; Rabel S; Nauka E; Casadevall G; Shivanand P; Eichenbaum G; Mansky P
Int J Pharm; 2008 Mar; 351(1-2):209-18. PubMed ID: 18054181
[TBL] [Abstract][Full Text] [Related]
12. Characterization of water-in-oil microemulsion for oral delivery of earthworm fibrinolytic enzyme.
Cheng MB; Wang JC; Li YH; Liu XY; Zhang X; Chen DW; Zhou SF; Zhang Q
J Control Release; 2008 Jul; 129(1):41-8. PubMed ID: 18474405
[TBL] [Abstract][Full Text] [Related]
13. A water-in-oil-in-oil-in-water (W/O/O/W) method for producing drug-releasing, double-walled microspheres.
Zheng W
Int J Pharm; 2009 Jun; 374(1-2):90-5. PubMed ID: 19446764
[TBL] [Abstract][Full Text] [Related]
14. Use of an in vitro model for the assessment of muscle damage from intramuscular injections: in vitro-in vivo correlation and predictability with mixed solvent systems.
Brazeau GA; Fung HL
Pharm Res; 1989 Sep; 6(9):766-71. PubMed ID: 2813273
[TBL] [Abstract][Full Text] [Related]
15. Development of an in situ forming PLGA drug delivery system I. Characterization of a non-aqueous protein precipitation.
Körber M; Bodmeier R
Eur J Pharm Sci; 2008 Nov; 35(4):283-92. PubMed ID: 18721875
[TBL] [Abstract][Full Text] [Related]
16. In vitro myotoxicity of selected cationic macromolecules used in non-viral gene delivery.
Brazeau GA; Attia S; Poxon S; Hughes JA
Pharm Res; 1998 May; 15(5):680-4. PubMed ID: 9619774
[TBL] [Abstract][Full Text] [Related]
17. An in vitro model to evaluate muscle damage following intramuscular injections.
Brazeau GA; Fung HL
Pharm Res; 1989 Feb; 6(2):167-70. PubMed ID: 2762216
[TBL] [Abstract][Full Text] [Related]
18. High-throughput study of phenytoin solid dispersions: formulation using an automated solvent casting method, dissolution testing, and scaling-up.
Barillaro V; Pescarmona PP; Van Speybroeck M; Thi TD; Van Humbeeck J; Vermant J; Augustijns P; Martens JA; Van Den Mooter G
J Comb Chem; 2008; 10(5):637-43. PubMed ID: 18627202
[TBL] [Abstract][Full Text] [Related]
19. Tyrosine kinase inhibitor loaded PCL microspheres prepared by S/O/W technique using ethanol as pretreatment agent.
Zhang Y; Zhang Y; Guo S; Huang W
Int J Pharm; 2009 Mar; 369(1-2):19-23. PubMed ID: 19041382
[TBL] [Abstract][Full Text] [Related]
20. Mucoadhesion, hydration and rheological properties of non-aqueous delivery systems (NADS) for the oral cavity.
Zaman MA; Martin GP; Rees GD
J Dent; 2008 May; 36(5):351-9. PubMed ID: 18343013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
